Microvascular invasion (MVI) is regarded as a sign of early metastasis in liver cancer and can be only diagnosed by a histopathology exam in the resected specimen. Preoperative prediction of MVI status may exert an effect on patient treatment management, for instance, to expand the resection margin.
1. Introduction
Microvascular invasion (MVI) has been recognized as an independent predictor for early recurrence and poor prognosis after liver resection or transplantation in hepatocellular carcinoma (HCC) [
1,
2]. Its reported incidence ranges from 15% to 57% according to different diagnostic criteria and study population [
3]. The diagnosis of MVI, however, is only made by a postoperative histopathology exam on the resected specimen, which exerts little or no influence on the patient treatment management, while with the knowledge of MVI, clinicians can optimize a patient treatment strategy, for example, to expand the resection margin in operation or to adopt an alternative treatment option. To implement personalized medicine, it is of utmost importance to preoperatively identify and stratify patients with MVI. Therefore, a reliable, noninvasive biomarker for preoperative prediction of MVI is urgently needed.
Medical imaging has evolved from a primarily diagnostic tool to an essential role in clinical decision making. Clinically, radiologists use pattern recognition after establishing links between radiological features at CT or MRI images and MVI [
4,
5], such as arterial peritumoral enhancement, non-smooth tumor margins, and rim arterial enhancement [
2]. The Liver Imaging Reporting and Data System (LI-RADS) has recently been developed and has evolved as a comprehensive and standardized diagnostic algorithm for HCC imaging reporting [
6]. LI-RADS has been proven to be an effective tool not only for HCC diagnosis but also for outcome prediction after liver resection, radiofrequency ablation, or liver transplantation [
6,
7,
8], exerting an increasing influence on the treatment management of HCC. Previous studies have demonstrated the diagnostic value of LI-RADS in the prediction of MVI [
9,
10]. However, these qualitative features suffer from their subjectivity and high inter-observer variability [
11].
Radiomics is an emerging field that can extract high-throughput imaging features from biomedical images and convert them into mineable data for quantitative analysis [
12,
13]. Its basic assumption lies on that the alterations and heterogeneity of the tumor on the micro scale (e.g., cell or molecular levels) can be reflected in the images [
14]. Therefore, through radiomics analysis, the cancerous cell emboli (i.e., MVI) in the hepatic vasculature can be detected in the preoperative images, which holds promise for the preoperative prediction of MVI and personalized treatment. In recent years, a number of radiomics models for MVI prediction have emerged. However, there has not been any research systematically summarizing current radiomics research for MVI prediction, and the overall efficacy of the prediction model is still unknown. In addition, as radiomics research is a sophisticated process and consists of several steps, it is important to evaluate the methodological variability to obtain a reliable and reproducible model before translating it to clinical applications.
2. General Characteristics and the Incidence of MVI
Studies were retrospectively designed and, in total, included 5552 patients with a sample size varying from 69 to 637 patients (median: 174). Most studies (20/22) split the cohort into a training and a test cohort, while only two of them further validated their model using an independent external cohort [
25,
29]. Nine studies (8/22) focused on solitary HCC, among which five focused on HCC with a diameter of less than 5 cm.
The incidence of MVI ranged from 25.3% to 67.5% for an individual entire cohort, and 25.3% to 56.4% for HCC less than 5 cm. Around two thirds (16/22) of the studies explicitly stated their definition of MVI. Table 1 gives more details about the general characteristics of the reviewed studies.
Table 1. Study and patient characteristics.
First Author |
Year |
Study Design |
No. of Patients (Train vs. Test Cohort) |
Independent Validation Cohort |
Age (Mean/Median) |
Gender (M/F, %) |
Indication |
MVI Incidence |
Jian Zheng [20] |
2017 |
R# |
120 (NA) |
No |
70 |
73/27 |
HCC |
44% |
Jie Peng [21] |
2018 |
R |
304 (184:120) |
No |
53 vs. 55 † |
85/15 |
HCC (solitary) |
66% |
Xiaohong Ma [22] |
2018 |
R |
157 (110:47) |
No |
53 vs. 55 † |
85/15 |
HCC (≤6 cm, solitary) |
35% |
ShiTing Feng [23] |
2019 |
R |
160 (110:50) |
No |
54.8 |
91/9 |
HCC |
38.8% |
Ming Ni [24] |
2019 |
R |
206 (148:58) |
No |
57 vs. 59 † |
NA |
HCC (>1 cm) |
42.7% |
Rui Zhang [25] |
2019 |
R |
267 (194:73) |
No |
57.9 |
86/14 |
HCC (solitary) |
33.7% |
Yong-Jian Zhu [26] |
2019 |
R |
142 (99:43) |
No |
57 |
87/13 |
HCC (<5 cm, solitary) |
37.3% |
Giacomo Nebbia [27] |
2020 |
R |
99 (NA) |
No |
51 vs. 54 (MVI vs. non-MVI) |
84/16 |
HCC |
61.6% |
Qiu-ping Liu [28] |
2020 |
R |
494 (346:148) |
No |
NA |
84/16 |
HCC |
30.2% |
Xiuming Zhang [29] |
2020 |
R |
637 (451:111) |
Yes (75, external) |
57.5 vs. 56.2 vs. 60.7 § |
86/14 |
HCC |
40% |
Yi-quan Jiang [30] |
2020 |
R |
405 (324:81) |
No |
48.5 |
85/15 |
HCC |
54.3% |
Mu He [31] |
2020 |
R |
163 (101:44) |
Yes (18, internal) |
50.0 vs. 47.5 vs. 52.0 § |
82/18 |
HCC |
67.5% |
Huan-Huan Chong [32] |
2021 |
R |
356 (250:106) |
No |
54.2 |
85/15 |
HCC (≤5 cm) |
25.3% |
Yidi Chen [33] |
2021 |
R |
269 (188:81) |
No |
51.5 |
81/19 |
HCC |
41.3% |
Youcai Li [34] |
2021 |
R |
80 (50:30) |
No |
NA |
91/9 |
HCC (BCLC 0/A) |
45% |
Danjun Song [35] |
2021 |
R |
601 (461:140) |
No |
56.5 |
82/18 |
HCC (solitary) |
37.40% |
Houjiao Dai [36] |
2021 |
R |
69 (LOOCV) |
No |
52.7 |
96/4 |
HCC (solitary) |
42.0% |
Peng Liu [37] |
2021 |
R |
185 (124:61) |
No |
54 vs. 52 † |
84/26 |
HCC (≤5 cm, solitary) |
34.1% |
Shuai Zhang [38] |
2021 |
R |
130 (91:39) |
No |
57.8 vs. 58.6 † |
68/32 |
HCC (>1 cm) |
61.5% |
Wanli Zhang [39] |
2021 |
R |
111 (88:23) |
No |
NA |
88/12 |
HCC |
51.4% |
Xiang-pan Meng [40] |
2021 |
R |
402 (300:102) |
No |
57 vs. 57 † |
85/15 |
HCC (solitary) |
40% |
Yang Zhang [41] |
2021 |
R |
195 (136:59) |
No |
57.7 |
88/12 |
HCC (≤5 cm) |
56.4% |
This entry is adapted from the peer-reviewed paper 10.3390/cancers13225864